Zoetis Inc. (NYSE:ZTS) Shares Bought by Campbell Newman Asset Management Inc.

Campbell Newman Asset Management Inc. boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,248 shares of the company’s stock after buying an additional 3,054 shares during the quarter. Zoetis accounts for approximately 1.4% of Campbell Newman Asset Management Inc.’s portfolio, making the stock its 29th largest holding. Campbell Newman Asset Management Inc.’s holdings in Zoetis were worth $16,506,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Callahan Advisors LLC grew its position in Zoetis by 90.4% during the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the period. CIBC Asset Management Inc lifted its holdings in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Schroder Investment Management Group lifted its stake in shares of Zoetis by 2.6% during the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock valued at $40,036,000 after buying an additional 6,169 shares during the period. Vanguard Group Inc. lifted its stake in shares of Zoetis by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after buying an additional 120,158 shares during the period. Finally, Portside Wealth Group LLC lifted its stake in shares of Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock valued at $5,550,000 after buying an additional 6,672 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus dropped their price target on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Finally, Morgan Stanley dropped their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $212.75.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president now directly owns 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Zoetis Price Performance

ZTS opened at $164.27 on Friday. The company has a fifty day simple moving average of $158.67 and a 200 day simple moving average of $164.01. The firm has a market cap of $73.13 billion, a price-to-earnings ratio of 30.03, a PEG ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business’s revenue was up 1.4% on a year-over-year basis. During the same period last year, the business earned $1.38 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis’s dividend payout ratio (DPR) is 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.